Sharda Cropchem Share Price Target 2026, 2027, 2028, 2029, 2030
- Market Cap
- ₹7,569 Cr
- Book Value
- ₹347
- Stock P/E
- 12.1
- Dividend Yield
- 1.78%
- ROE
- 23.2%
- ROCE
- 30.3%
- PEG Ratio
- 0.51
- EV/EBITDA
- 6.4
Fundamentals from Screener.in, as of 5 Aug 2026. Live price via Yahoo Finance.
Technical snapshot
EOD ·Sharda Cropchem Ltd closed at ₹770.70 on 19 August 2026, down 0.1% on the day, 11.1% below its 50-day average, 40.6% below its 52-week high, with volume at 1.31× its 20-session average.
- RSI 14
- 23.5
- vs 50-day SMA
- -11.1%
- vs 200-day SMA
- -17.9%
- From 52-week high
- -40.6%
- Relative volume
- 1.31×
- 20-day return
- -11.7%
End-of-day prices from exchange-published files (NSE/BSE bhavcopy), updated after market close. Descriptive statistics, not investment advice.
Sharda Cropchem share price today
Sharda Cropchem (NSE: SHARDACROP) runs agrochemicals’ most misunderstood model: it owns no plants. Its asset is a library of 4,000+ product registrations — the regulatory licences to sell generic crop-protection molecules across Europe, the Americas and beyond — earned through years-long, capital-cheap dossier work. Manufacturing is sourced (mostly China), branding is local, and the registration library does what factories cannot: it compounds, transfers nowhere, and depreciates never.
The market’s chronic suspicion of the model is visible in the price: 12.1× earnings, PEG 0.51, EV/EBITDA 6.4 — for a business earning 30.3% ROCE with zero debt and paying 1.78%. That discount reflects China sourcing and generic-pricing margin swings as much as the registration library’s value.
The registration library
Each registration is a mini-moat: country-by-country regulatory approval that takes years and specialist skill to earn, then sells product against it indefinitely. Sharda’s pipeline keeps adding registrations (the true capex line), and the spread between China sourcing costs and Western generic prices is the margin engine — volatile quarter to quarter but structurally positive across cycles. Working capital, not factories, is the balance-sheet story; net cash keeps it comfortable.
What matters next: agrochem generic pricing (the margin swing), China supply-chain continuity, registration-pipeline additions, and European agricultural policy shifts.
The numbers
Financial snapshot — 5 August 2026
| Metric | Value |
|---|---|
| Market cap | ₹7,569 Cr |
| P/E (TTM) | 12.1 |
| EV/EBITDA | 6.4 |
| Operating margin | 19.5% |
| ROE / ROCE | 23.2% / 30.3% |
| Debt to equity | 0.00 (net cash) |
| Sales CAGR (5y) | 17.1% |
| Profit CAGR (5y) | 23.8% |
| Promoter holding | 74.8% |
| EPS (TTM) | ₹69.53 |
Sharda Cropchem share price target 2026 to 2030
EPS base ₹69.53 (TTM). Bear: generic pricing turns down again — 4% growth, multiple at 8×. Base: the library compounds normally — 12% growth at 11×. Bull: an agrochem upcycle re-rates the model — 18% growth at 14×.
From ₹841, the base case is ≈ +60% over four and a half years plus the 1.78% yield; the bear is −19%. At 12×, part of the cyclical risk is already reflected, but another pricing downturn can still overwhelm the asset-light economics.
What supports the case
- A 4,000-registration library — regulatory moats that compound without capex.
- 30% ROCE, net cash, zero factories to depreciate or maintain.
- 12× with PEG 0.51 — the market’s suspicion is the entry discount.
- Generic crop-protection demand is structural: patents keep expiring.
- A 1.78% yield funded by a working-capital-light model.
The risks: margins swing with China sourcing costs and Western generic pricing, geopolitical supply-chain shocks hit the model’s core, and asset-light businesses get no asset-value floor in panics.
What to weigh at the current price
The tension is whether Sharda’s registration library can keep compounding before China sourcing costs or another generic-pricing downturn erodes the margin that makes 12.1× look inexpensive.
FAQ
What is the Sharda Cropchem share price target for 2030? The table above sets out bear, base and bull scenarios for each year to 2030. They are valuation sensitivities, not promised prices.
How does a company with no plants earn 30% ROCE? The capital is the registration library and working capital, both modest against the profits the licences enable — asset-light economics agrochemicals rarely see.
Why does the market keep it this cheap? China-sourcing dependence, margin volatility, and a model that doesn’t fit standard chemical-sector templates. The accumulate case is that 12× over-discounts all three.
When are Sharda Cropchem’s next results? Check the results calendar and confirm the announced date in the relevant exchange filing.
This article is research and education, not personalised investment advice. We are not SEBI-registered advisers. Price targets are scenario arithmetic, not promises. Do your own research and consult a registered adviser before acting.